Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
Phase 2
Completed
- Conditions
- Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)Human Immunodeficiency Virus Infections
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 245
- Registration Number
- NCT00294164
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis Subjects
Phase 3
Completed
- Conditions
- Multiple Sclerosis, Relapsing-remitting
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1883
- Registration Number
- NCT00292253
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
Phase 3
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2013-08-05
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 677
- Registration Number
- NCT00292266
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2005-12-06
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 509
- Registration Number
- NCT00262314
- Locations
- 🇺🇸
Registrat Inc, Lexington, Kentucky, United States
A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
Phase 3
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2013-08-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 257
- Registration Number
- NCT00249860
A Phase 3b Study to Evaluate Subject Satisfaction With Follitropin Alfa Injection in Oligoanovulatory Infertile Women Undergoing Ovulation Induction
Phase 3
Completed
- Conditions
- Infertility
- First Posted Date
- 2005-10-03
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 62
- Registration Number
- NCT00230815
Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction
Phase 2
Completed
- Conditions
- Anovulation
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 271
- Registration Number
- NCT00213148
- Locations
- 🇺🇸
Local US Medical Information, Rockland, Massachusetts, United States
A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Phase 3
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2014-02-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1326
- Registration Number
- NCT00213135
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
Phase 1
Completed
- Conditions
- Colorectal CancerOvarian CancerCarcinoma, Non-small-cell LungProstate Cancer
- Interventions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2013-10-25
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 45
- Registration Number
- NCT00132522
- Locations
- 🇺🇸
City of Hope, Durate, California, United States
🇺🇸Dartmouth Medical School, Pharmacology & Toxicology Dept. of Medicine, Lebanon, New Hampshire, United States
🇺🇸Fox Chase Cancer Oncology Department of Medical Oncology, Philadelphia, Pennsylvania, United States
Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer
Phase 2
Completed
- Conditions
- Lung CancerNon Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2005-05-27
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 150
- Registration Number
- NCT00111839
- Locations
- 🇺🇸
Arizona Clinical Research Center, Tucson, Arizona, United States
🇺🇸University of Arkansas, Arkansas Cancer Research Center, Little Rock, Arkansas, United States
🇺🇸University of Southern California/Norris Cancer Center, Los Angeles, California, United States